CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The AB-DiRecT project investigates gepotidacin, a novel antibacterial, for treating infections caused by resistant strains of Neisseria gonorrhoeae and Escherichia coli. The study will assess gepotidacin's tissue distribution and potential efficacy through various pharmacokinetic models.
Antimicrobial resistance imposes an important health and economic burden with the threat of a future without effective antibiotics requiring major changes to contemporary healthcare provision.
Therefore, the discovery and development of novel mechanism of action agents able to treat resistant infections is a key urgent need.
Gepotidacin is a first in class, novel triazaacenaphthylene antibacterial that is being developed by GSK.
Due to its novel mechanism of action, gepotidacin is active in vi…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Poitiers Cedex
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
United Kingdom, LONDON
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
MEDIZINISCHE UNIVERSITAET WIEN
Austria, Wien
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Poitiers Cedex
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
